Loading clinical trials...
Loading clinical trials...
Safety and Immunogenicity of 3 Lots of GSK Biologicals' Novel Adjuvanted Hepatitis B Vaccine, Administered According to a 2 Dose Schedule, and Engerix™-B Administered According to a 3 Dose Schedule to Healthy Volunteers ≥ 15 Years of Age
Conditions
Interventions
HBV-MPL vaccine 208129
Engerix™-B
Locations
7
Australia
GSK Clinical Trials Call Center
Parkville, Victoria, Australia
GSK Clinical Trials Call Center
Hradec Kralové, Czechia
GSK Clinical Trials Call Center
München, Germany
GSK Clinical Trials Call Center
Bari, Italy
GSK Clinical Trials Call Center
Utrecht, Netherlands
GSK Clinical Trials Call Center
Lausanne, Switzerland
Start Date
April 1, 1999
Primary Completion Date
February 1, 2000
Last Updated
June 13, 2008
NCT07024641
NCT06671093
NCT07275554
NCT03826433
NCT06885710
NCT06947499
Lead Sponsor
GlaxoSmithKline
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions